Skip to main content
Search
Newsletters
Watchlist
Latest in
Biotechnology
Follow
You must be logged in to follow.
Log In
Create free account
Latest
report on business
AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion
March 19, 2024
property report
Plans for a mass-timber building pivot to steel girders and concrete
January 16, 2024
investment ideas
Deals, data buzz could help biotech shares exit Wall Street’s ‘no man’s land’
October 15, 2021
report on business
Field Trip Health raises largest financing in Canada for a psychedelics company
March 17, 2021
report on business
B.C.’s Eupraxia Pharmaceuticals sees lacklustre trading debut
March 9, 2021
advisor etfs
Why the nascent psychedelics industry is getting investors’ attention
March 2, 2021
report on business
First TSX-only biotech IPO in 18 years set for next week as Eupraxia closes books on $41-million offering
March 1, 2021
report on business
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding
February 10, 2021
report on business
TMX CEO aims to encourage small biotech companies to list in Canada
February 9, 2021
report on business
RBC taps into biotech surge, investing in new Lumira venture fund
February 1, 2021
report on business
Vancouver’s Khosrowshahi family to launch US$400-million pharma IPO, capitalizing on biotech craze
January 25, 2021
report on business
Rare milestone approaches for Canadian biotech sector as Aurinia awaits FDA OK to sell new drug
January 17, 2021
report on business
AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO
January 7, 2021
opinion
What Canada needs to do to build a world-class biotech sector
Roberto Bellini
December 23, 2020
report on business
AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million
December 16, 2020
number cruncher
Which of these top 10 Canadian biotech stocks are undervalued?
December 14, 2020
international business
AstraZeneca shares fall as investors react to $39-billion Alexion acquisition
December 14, 2020
international business
AstraZeneca to buy U.S. drugmaker Alexion for $39-billion to expand in immunology
December 12, 2020
report on business
Vancouver’s AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech
December 7, 2020
investment ideas
Cowen’s CEO sees gains in biotech, helped by easier access to cash
December 2, 2020
Load More Articles